Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
jRCT1080223858Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma, transformed (t-FL) and 1 more, sponsored by Gilead Sciences. Primary endpoint: Overall response rate. Started Apr 2018; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma, transformed (t-FL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT1080223858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223858.